Photo of Jacob D. Soumerai, MD

Jacob D. Soumerai, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000


jsoumerai@mgh.harvard.edu

Photo of Jacob D. Soumerai, MD

Massachusetts General Hospital
Phone: (617) 724-4000


jsoumerai@mgh.harvard.edu

Visualize Collaborations

Jacob D. Soumerai, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Clinical Investigator in Lymphoma, Medicine, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Soumerai JD, Thompson MC, Dogan A, Seshan VE, Flaherty K, Slupe N, Carter J, Hochberg E, Barnes JA, Abramson JS, Noy A, Owens CN, Palomba ML, Kumar A, Roeker LE, Takvorian RW, Epstein-Peterson ZD, Geyer MB, Salles GA, Stuver RN, Caron PC, Islam P, Haque T, Ghione P, Steiner RE, Torka P, David KA, Lue JK, Hamlin PA, Moskowitz AJ, Falchi L, Haydu JE, Johnson PC, Mi J, Mahajan N, Pendleton J, Labarre A, Chabowska M, Choma M, Grieve C, Joseph A, Dorsey C, Brutus J, Martignetti R, Nazzaro R, Coyle J, Maas OG, Meemanage Z, Simkins E, Kakolu A, Gordan C, Baez E, Beatty B, Apazidis A, Gulotta M, Ratcliff S, Hirata J, Shahkarami M, Jacob AP, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs. Blood Adv 2026. PubMed
  • Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar AJ, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS. A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation. Blood Adv 2026. PubMed
  • Soumerai JD, Wierda WG. Developing MRD as an early endpoint for accelerated approval in CLL. Semin Hematol 2026. PubMed
  • Haydu JE, Lei MM, Redd RA, Barnes JA, Darnell EP, Hochberg EP, Johnson PC, Takvorian RW, Weitzman JI, Woods EC, Hurvitz TL, Lafranchi CD, Livingstone P, Lynch JM, Patterson EN, Malespini JE, McGree BM, Santilli AO, Thorp KA, Sherburne MM, Wardrop LB, Lou UY, Sorial MN, Cho C, Ford J, Nemac R, Soumerai JD, Abramson JS. A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma. 2025; 2:100147. PubMed
  • Haydu JE, Redd RA, Lei MM, Hochberg E, Barnes JA, Armand P, Soumerai JD, Eichler A, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany IC, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS. A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma. Blood Adv 2025. PubMed
  • Soumerai JD, Davids MS. Triplet Therapies in Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am 2025. PubMed
  • Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg E, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy. Blood 2025. PubMed
  • Pullarkat P, Lei M, Redd R, Rana R, Lou U, Sorial M, Rowen B, Kim EB, Medrano A, Haydu JE, Barnes J, Hochberg E, Johnson PC, Takvorian R, Lynch J, Patterson E, Thorp K, Sherburne M, McGree B, Ford J, Nemec R, Cho C, Abramson J, Soumerai JD. Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study. 2025; 2:100075. PubMed
  • Kim TM, Lakhani NJ, Soumerai J, Kamdar M, Gainor JF, Messersmith W, Fanning P, Guan S, Jin F, Forgie A, Wan HI, Pons J, Randolph SS, Kim WS. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica 2025. PubMed
  • Ababneh HS, Ng AK, Wan J, Walburn T, Zhu L, Bobić M, Johnson PC, Bredtfeld J, Leeman J, Soumerai J, Abramson JS, Barnes J, Takvorian R, Frigault MJ, Pursley J, Patel CG. 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma. Int J Radiat Oncol Biol Phys 2025. PubMed
  • Yoon JT, Zhou Y, Mikhaleva M, Choi DS, Fernandes SM, Armand P, Bessnow AC, Crombie JL, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Merryman RW, Odejide OO, Parry EM, Qualls DA, Ryan CE, Sekar A, Soumerai JD, Arnason JE, Tyekucheva S, Davids MS, Brown JR, Ahn IE. Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia. Blood Adv 2025. PubMed
  • Johnson PC, Abramson JS, LaCasce AS, Armand P, Barnes J, Merryman RW, Soumerai J, Hochberg E, Takvorian RW, Jacobson CA, Crombie JL, Fisher DC, Schwartz J, Friedman RS, Stacey J, Yang D, Coffey B, Markowitz N, Odejide OO, El-Jawahri A. Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy. J Natl Compr Canc Netw 2025. PubMed
  • Soumerai JD, Barrientos JC, Ahn IE, Coombs CC, Gladstone DE, Hoffmann MS, Kittai AS, Jacobs RW, Lipsky A, Patel K, Rhodes JM, Skarbnik AP, Thompson MC, Ermann DA, Reville PK, Shah HR, Brown JR, Stephens DM. Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Adv 2024. PubMed
  • Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Martinez-Lage M, Shankar G, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis. Am J Hematol 2024. PubMed
  • Kumar A, Soumerai JD, Abramson JS, Barnes JA, Caron PC, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly H, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz AJ, Owens CN, Plummer S, Puccio M, Salles GA, Seshan VE, Simkins E, Slupe N, Zhang H, Zelenetz AD. Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation. Blood 2024. PubMed
  • Soumerai JD, Yousif Z, Gift T, Desai R, Huynh L, Ye M, Banatwala A, Clear L, Pinaire M, Belsky G, Hsieh YG, Herrick C, Darnell EP, Duh MS, Sanchirico M, Murphy SN. IgG Testing, Immunoglobulin Replacement Therapy, and Infection Outcomes in Patients with CLL or NHL: Real-World Evidence. Blood Adv 2024. PubMed
  • Soumerai JD, Diefenbach CS, Jagadeesh D, Asch A, Kumar A, Tsai ML, Jandl TA, Lossos IS, Kenkre VP, Awan F, Novotny W, Huang J, Miao L, Rajagopalan P, Ghalie RG, Zelenetz AD. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology 2024. PubMed
  • Nemec R, Scherrer-Crosbie M, Abramson JS, Redd R, Gilman HK, Ho T, Wu J, Heemelaar J, Neuberg D, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Friedman RS, LaCasce AS, Neilan TG, Soumerai JD. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP. Leuk Lymphoma 2024. PubMed
  • Lei MM, Sorial MN, Lou U, Yu M, Medrano A, Ford J, Nemec RA, Abramson JS, Soumerai JD. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leuk Lymphoma 2024. PubMed
  • Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B. A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings. 2024; 15:1369619. PubMed
  • Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, Patel CG. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma. Hematol Oncol 2023. PubMed
  • Redd RA, Ford J, Lei M, Abramson JS, Soumerai JD. Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes. Leuk Lymphoma 2023. PubMed
  • Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA 2023; 330:528-536. PubMed
  • Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J. Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells. 2023. PubMed
  • Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 2023. PubMed
  • Bantilan KS, Kay NE, Parikh SA, Rabe KG, Call TG, Leis JF, Ding W, Slager SL, Soumerai JD, Roeker LE, Mato A, Zelenetz AD. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leuk Lymphoma 2022. PubMed
  • Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, O'Donnell EK, Saucier A, Jacobson CA, Frigault MJ, Raje NS. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J 2022; 12:146. PubMed
  • Soumerai JD, Takvorian RW, Sohani AR, Abramson JS, Ferry JA. Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. Lancet Haematol 2022; 9:e796. PubMed
  • Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach. Clin Cancer Res 2022. PubMed
  • Soumerai JD, Rosenthal AC, Harkins SK, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri A, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan KS, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood 2022. PubMed
  • Pagel JM, Soumerai JD, Reddy N, Jagadeesh D, Stathis A, Asch A, Salman H, Kenkre VP, Iasonos A, Llorin-Sangalang J, Li J, Zelenetz AD. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022; 23:1021-1030. PubMed
  • Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin M, Regan C, Blumenthal KG, Banerji A, Judd AD, Scorsune KJ, McGree BM, Sherburne MM, Lynch JM, Weitzman JI, Lei M, Kotton CN, Dighe AS, Maus MV, Alter G, Abramson JS, Soumerai JD. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv 2022; 6:1671-1683. PubMed
  • Fischer T, Ni A, Bantilan KS, Soumerai JD, Alperovich A, Batlevi C, Younes A, Zelenetz AD. The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leuk Lymphoma 2022; 63:573-582. PubMed
  • Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol 2021; 8:e879-e890. PubMed
  • Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2021. PubMed
  • Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 2020; 10:74. PubMed
  • Soumerai JD, Ni A, Alperovich A, Batlevi C, Bantilan KS, Fischer T, Copeland AR, Smith K, Ying Z, Younes A, Zelenetz AD. Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. Leuk Lymphoma 2020. PubMed
  • Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135:1912-1915. PubMed
  • Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol 2019; 6:e366-e374. PubMed
  • Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma 2019. PubMed
  • Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood 2019. PubMed
  • Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma 2018. PubMed
  • Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res 2017. PubMed
  • Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91:E436-41. PubMed
  • Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control 2014; 21:266-78. PubMed
  • Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, Abramson JS. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014; 55:538-43. PubMed
  • Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118:276-81. PubMed
  • Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830-5. PubMed
  • Treon SP,Branagan AR,Ioakimidis L,Soumerai JD,Patterson CJ,Turnbull B,Wasi P,Emmanouilides C,Frankel SR,Lister A,Morel P,Matous J,Gregory SA,Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009; 113:3673-8. PubMed
  • Leleu X,Hunter ZR,Xu L,Roccaro AM,Moreau AS,Santos DD,Hatjiharissi E,Bakthavachalam V,Adamia S,Ho AW,Soumerai J,Patterson CJ,Manning RJ,Hamilton S,Verselis S,Fox E,Carrasco R,Ghobrial IM,Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. British Journal of Haematology 2009; 145:59-63. PubMed
  • Ioakimidis L,Patterson CJ,Hunter ZR,Soumerai JD,Manning RJ,Turnbull B,Sheehy P,Treon SP. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:62-6. PubMed
  • Leleu X,Tamburini J,Roccaro A,Morel P,Soumerai J,Levy V,Wemeau M,Balkaran S,Poulain S,Hunter ZR,Ghobrial IM,Treon SP,Leblond V. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma 2009; 9:71-3. PubMed
  • Leleu X,Xu L,Jia X,Sacco A,Farag M,Hunter ZR,Moreau AS,Ngo HT,Hatjiharissi E,Ho AW,Santos DD,Adamia S,O'Connor K,Ciccarelli B,Soumerai J,Manning RJ,Patterson CJ,Roccaro AM,Ghobrial IM,Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2009; 113:626-34. PubMed
  • Leleu X,Soumerai J,Roccaro A,Hatjiharissi E,Hunter ZR,Manning R,Ciccarelli BT,Sacco A,Ioakimidis L,Adamia S,Moreau AS,Patterson CJ,Ghobrial IM,Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250-5. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Chu L,Musto P,Baron AD,Nunnink JC,Kash JJ,Terjanian TO,Hyman PM,Nawfel EL,Sharon DJ,Munshi NC,Anderson KC. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355-60. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Briccetti FM,Pasmantier M,Zimbler H,Cooper RB,Moore M,Hill J 2nd,Rauch A,Garbo L,Chu L,Chua C,Nantel SH,Lovett DR,Boedeker H,Sonneborn H,Howard J,Musto P,Ciccarelli BT,Hatjiharissi E,Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-7. PubMed
  • Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Blood 2008; 112:4683-9. PubMed
  • Moreau AS,Jia X,Patterson CJ,Roccaro AM,Xu L,Sacco A,O'Connor K,Soumerai J,Ngo HT,Hatjiharissi E,Hunter ZR,Ciccarelli B,Manning R,Ghobrial IM,Leleu X,Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. British Journal of Haematology 2008; 142:775-85. PubMed
  • Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7 Suppl 5:S199-206. PubMed
  • Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol 2007; 82:83-4. PubMed
Hide
Visualize Collaborations